NARA Discovery
Article Details
← Back to Search Results
Journal Article

Further evaluation of the efficacy of emamectin benzoate for treating Pseudocapillaria tomentosa (Dujardin 1843) in zebrafish Danio rerio (Hamilton 1822)

Michael L. Kent; Virginia Watral; Christopher A. Gaulke; Thomas J. Sharpton
Journal of Fish Diseases · Vol. 42, Issue 10 · pp. 1351-1357 · 2019

Abstract

Pseudocapillaria tomentosa is a pathogenic nematode parasite, causing emaciation and severe inflammatory lesions in the intestines in zebrafish Danio rerio (Hamilton 1822). Emamectin benzoate is commercially available analogue of ivermectin used for treating salmon for sea lice, under the brand name SLICE ® , and we have used this for treating zebrafish with the P. tomentosa . Here, SLICE ® , 0.2 per cent active emamectin benzoate, was used for oral treatments at 0.35 mg emamectin benzoate/kg fish/day for 14 days starting at 7 days post‐exposure (dpe). Another experiment entailed initiating treatment during clinical disease (starting at 28 dpe). Early treatment was very effective, but delaying treatment was less so, presumably due to inappetence in clinically affected fish. We evaluated emamectin benzoate delivered in water, using Lice‐Solve™ (mectinsol; 1.4% active emamectin benzoate) in two experiments. Application of four 24‐hr treatments, space over 7 days was initiated at 28 dpe at either 0.168 or 0.56 mg emamectin benzoate/L/bath, and both treatments completely eradicated infections. This was 3 or 10 times manufacture's recommended dose, but was not associated with clinical or histological side effects.

Bibliographic Information

JournalJournal of Fish Diseases
PublisherWiley
Publication Date2019-10-01
Publication Year2019
Volume42
Issue10
Pages1351-1357
Document TypeJournal Article
Print ISSN0140-7775
eISSN1365-2761
DOI10.1111/jfd.13057
SubjectGeneral Aquaculture, Fisheries & Fish Science

Access Information

NARA Access Coverage1997-01-01~Current
Journal Homepagehttps://onlinelibrary.wiley.com/loi/13652761
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.